Alzheimer's disease: The two-hit hypothesis

Lancet Neurology

Volumn 3, Issue 4, 2004, Pages 219-226

  Zhu, Xiongwei ^a   Raina, Arun K ^a   Perry, George ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN E; PROTEIN P21; PROTEIN P27; PROTEIN P53; TAU PROTEIN;

ALZHEIMER DISEASE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; DNA REPLICATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; MITOSIS INDEX; MITOSIS INHIBITION; NERVE CELL DEGENERATION; ONCOGENE RAS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; CELL CYCLE; HUMANS; LINKAGE (GENETICS); MEMBRANE PROTEINS; MITOSIS; OXIDATIVE STRESS; PRESENILIN-1; PRESENILIN-2; SIGNAL TRANSDUCTION;

EID: 1642358352     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00707-0     Document Type: Review

References (139)

1. Smith M.A. Alzheimer's disease. Int Rev Neurobiol. 42:1998;1-54.
2. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:1995;211-219.
3. Sherr C.J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
4. Meikrantz W., Schlegel R. Apoptosis and the cell cycle. J Cell Biochem. 58:1995;160-174.
5. Raina A.K., Zhu X., Rottkamp C.A., Monteiro M., Takeda A., Smith M.A. Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer's disease. J Neurosci Res. 61:2000;128-133.
6. Zhu X., Raina A.K., Smith M.A. Cell cycle events in neurons: proliferation or death? Am J Pathol. 155:1999;327-329.
7. McShea A., Harris P.L., Webster K.R., Wahl A.F., Smith M.A. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol. 150:1997;1933-1939.
8. Nagy Z., Esiri M.M., Smith A.D. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol (Berl). 93:1997;294-300.
9. Nagy Z., Esiri M.M., Cato A.M., Smith A.D. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl). 94:1997;6-15.
10. Smith T.W., Lippa C.F. Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J Neuropathol Exp Neurol. 54:1995;297-303.
11. Yang Y., Geldmacher D.S., Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 21:2001;2661-2668.
12. Vincent I., Jicha G., Rosado M., Dickson D.W. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci. 17:1997;3588-3598.
13. Ogawa O., Zhu X., Lee H.G., et al. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathol (Berl). 105:2003;524-528.
14. Bowen R.L., Smith M.A., Harris P.L., et al. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res. 70:2002;514-518.
15. Bowser R., Smith M.A. Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J Alzheimers Dis. 4:2002;249-254.
16. Busser J., Geldmacher D.S., Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci. 18:1998;2801-2807.
17. McShea A., Harris P.L., Webster K.R., Wahl A.F., Smith M.A. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol. 150:1997;1933-1939.
18. Zhu X., Rottkamp C.A., Raina A.K., et al. Neuronal CDK7 in hippocampus is related to aging and Alzheimer's disease. Neurobiol Aging. 21:2000;807-813.
19. Vincent I., Zheng J.H., Dickson D.W., Kress Y., Davies P. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol Aging. 19:1998;287-296.
20. Yang Y., Mufson E.J., Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 23:2003;2557-2563.
21. Connor B., Young D., Lawlor P., et al. Trk receptor alterations in Alzheimer's disease. Brain Res Mol Brain Res. 42:1996;1-17.
22. Crutcher K.A., Scott S.A., Liang S., Everson W.V., Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci. 13:1993;2540-2550.
23. Allen S.J., MacGowan S.H., Treanor J.J., Feeney R., Wilcock G.K., Dawbarn D. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett. 131:1991;135-139.
24. Birecree E., Whetsell W.O. Jr, Stoscheck C., King L.E. Jr, Nanney L.B. Immunoreactive epidermal growth factor receptors in neuritic plaques from patients with Alzheimer's disease. J Neuropathol Exp Neurol. 47:1988;549-560.
25. Styren S.D., Mufson E.J., Styren G.C., Civin W.H., Rogers J. Epidermal growth factor receptor expression in demented and aged human brain. Brain Res. 512:1990;347-352.
26. Masliah E., Mallory M., Alford M., Deteresa R., Saitoh T. PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Neurobiol Aging. 16:1995;549-556.
27. Fenton H., Finch P.W., Rubin J.S., et al. Hepatocyte growth factor (HGF/SF) in Alzheimer's disease. Brain Res. 779:1998;262-270.
28. Connor B., Beilharz E.J., Williams C., et al. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Brain Res Mol Brain Res. 49:1997;283-290.
29. Tham A., Nordberg A., Grissom F.E., Carlsson-Skwirut C., Viitanen M., Sara V.R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer's type. J Neural Transm Park Dis Dement Sect. 5:1993;165-176.
30. Stopa E.G., Gonzalez A.M., Chorsky R., et al. Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun. 171:1990;690-696.
31. Gomez-Pinilla F., Cummings B.J., Cotman C.W. Induction of basic fibroblast growth factor in Alzheimer's disease pathology. Neuroreport. 1:1990;211-214.
32. Lombardi V.R., Garcia M., Rey L., Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol. 97:1999;163-171.
33. Xiang Z., Ho L., Valdellon J., et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 23:2002;327-334.
34. Copani A., Condorelli F., Caruso A., et al. Mitotic signaling by beta-amyloid causes neuronal death. Faseb J. 13:1999;2225-2234.
35. Giovanni A., Wirtz-Brugger F., Keramaris E., Slack R., Park D.S. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death. J Biol Chem. 274:1999;19011-19016.
36. Munch G., Gasic-Milenkovic J., Arendt T. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. J Neural Transm Suppl. 65:2003;63-71.
37. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
38. Kitamura Y., Shimohama S., Koike H., et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor- gamma in Alzheimer's disease brains. Biochem Biophys Res Commun. 254:1999;582-586.
39. Chang F., Steelman L.S., Shelton J.G., et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 22:2003;469-480.
40. Zhu X., Lee H-G, Perry G., Raina A.K., Smith M.A. The MAPK Pathways in Alzheimer's Disease. NeuroSignals. 11:2002;270-281.
41. Gartner U., Holzer M., Heumann R., Arendt T. Induction of p21ras in Alzheimer's pathology. Neuroreport. 6:1995;1441-1444.
42. Gartner U., Holzer M., Arendt T. Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience. 91:1999;1-5.
43. Luth H.J., Holzer M., Gertz H.J., Arendt T. Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly co-localized with p21ras and p16INK4a. Brain Res. 852:2000;45-55.
44. McShea A., Zelasko D.A., Gerst J.L., Smith M.A. Signal transduction abnormalities in Alzheimer's disease: evidence of a pathogenic stimuli. Brain Res. 815:1999;237-242.
45. Zhu X., Sun Z., Lee H.G., Siedlak S.L., Perry G., Smith M.A. Distribution, levels, and activation of MEK1 in Alzheimer's disease. J Neurochem. 86:2003;136-142.
46. Ferrer I., Blanco R., Carmona M., et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 11:2001;144-158.
47. Pei J.J., Braak H., An W.L., et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res. 109:2002;45-55.
48. Perry G., Lipphardt S., Mulvihill P., et al. Amyloid precursor protein in senile plaques of Alzheimer's disease. Lancet. 2:1988;746.
49. Zhu X., Castellani R.J., Takeda A., et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer's disease: the 'two-hit' hypothesis. Mech Ageing Dev. 123:2001;39-46.
50. Ferrer I., Blanco R., Carmona M., Puig B. Phosphorylated c-MYC expression in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Neuropathol Appl Neurobiol. 27:2001;343-351.
51. Smith M.A., Sayre L.M., Monnier V.M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
52. Nunomura A., Perry G., Pappolla M.A., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 19:1999;1959-1964.
53. Nunomura A., Perry G., Pappolla M.A., et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol. 59:2000;1011-1017.
54. Nunomura A., Perry G., Aliev G., et al. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol. 60:2001;759-767.
55. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 36:1994;747-751.
56. Mecocci P., Beal M.F., Cecchetti R., et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol. 31:1997;53-64.
57. de la Monte S.M., Luong T., Neely T.R., Robinson D., Wands J.R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest. 80:2000;1323-1335.
58. Colurso G.J., Nilson J.E., Vervoort L.G. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci. 73:2003;1795-1803.
59. Adamec E., Vonsattel J.P., Nixon R.A. DNA strand breaks in Alzheimer's disease. Brain Res. 849:1999;67-77.
60. Lucassen P.J., Chung W.C., Kamphorst W., Swaab D.F. DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer's disease in the absence of apoptotic morphology. J Neuropathol Exp Neurol. 56:1997;887-900.
61. Tobi S.E., Itzhaki R.F. DNA double-strand breaks measured by pulsed-field gel electrophoresis in irradiated lymphocytes from normal humans and those with Alzheimer's disease. Int J Radiat Biol. 63:1993;617-622.
62. Mullaart E., Boerrigter M.E., Ravid R., Swaab D.F., Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging. 11:1990;169-173.
63. Smith M.A., Perry G., Richey P.L., et al. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
64. Williamson K.S., Gabbita S.P., Mou S., et al. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer's brain. Nitric Oxide. 6:2002;221-227.
65. Castegna A., Aksenov M., Aksenova M., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain, part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 33:2002;562-571.
66. Castegna A., Aksenov M., Thongboonkerd V., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain, part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 82:2002;1524-1532.
67. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol. 149:1996;21-28.
68. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci. 17:1997;2653-2657.
69. Castegna A., Thongboonkerd V., Klein J.B., Lynn B., Markesbery W.R., Butterfield D.A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem. 85:2003;1394-1401.
70. Cras P., Smith M.A., Richey P.L., Siedlak S.L., Mulvihill P., Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer's disease. Acta Neuropathol. 89:1995;291-295.
71. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med. 7:2001;548-554.
72. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 19:1998;33-36.
73. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
74. Tamaoka A., Miyatake F., Matsuno S., et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology. 54:2000;2319-2321.
75. Palmer A.M., Burns M.A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645:1994;338-342.
76. Guan Z., Wang Y., Cairns N.J., Lantos P.L., Dallner G., Sindelar P.J. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer's disease. J Neuropathol Exp Neurol. 58:1999;740-747.
77. Castellani R.J., Harris P.L., Sayre L.M., et al. Active glycation in neurofibrillary pathology of Alzheimer's disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med. 31:2001;175-180.
78. Vitek M.P., Bhattacharya K., Glendening J.M., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci USA. 91:1994;4766-4770.
79. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging. 22:2001;397-402.
80. Riviere S., Birlouez-Aragon I., Vellas B. Plasma protein glycation in Alzheimer's disease. Glycoconj J. 15:1998;1039-1042.
81. Takeda A., Yasuda T., Miyata T., et al. Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer's disease brain. Acta Neuropathol (Berl). 95:1998;555-558.
82. Ko L.W., Ko E.C., Nacharaju P., et al. An immunochemical study on tau glycation in paired helical filaments. Brain Res. 830:1999;301-313.
83. Takeda A., Smith M.A., Avila J., et al. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem. 75:2000;1234-1241.
84. Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol. 140:1992;621-628.
85. Lee S.C., Zhao M.L., Hirano A., Dickson D.W. Inducible nitric oxide synthase immunoreactivity in the Alzheimer's disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol. 58:1999;1163-1169.
86. Aksenov M.Y., Tucker H.M., Nair P., et al. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Mol Neurosci. 11:1998;151-164.
87. Smith M.A., Kutty R.K., Richey P.L., et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol. 145:1994;42-47.
88. Perry G., Smith M.A. Is oxidative damage central to the pathogenesis of Alzheimer's disease? Acta Neurol Belg. 98:1998;175-179.
89. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer's amyloidosis. J Neurosci. 21:2001;4183-4187.
90. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 336:1997;1216-1222.
91. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
92. Mielke K., Herdegen T. JNK and p38 stresskinases: degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol. 61:2000;45-60.
93. Zhu X., Raina A.K., Rottkamp C.A., et al. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 76:2001;435-441.
94. Shoji M., Iwakami N., Takeuchi S., et al. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res. 85:2000;221-233.
95. Ferrer I., Blanco R., Carmona M., Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm. 108:2001;1397-1415.
96. Pei J.J., Braak E., Braak H., et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis. 3:2001;41-48.
97. Zhu X., Rottkamp C.A., Zevez K., Atwood C.S., Perry G., Smith M.A. Metal-mediated amyloid-beta toxicity acts through the activation of JNK/SAPK pathway in Alzheimer's disease. Free Radic Biol Med. 31:(suppl 1):2001;S65.
98. Perry G., Nunomura A., Smith M.A. A suicide note from Alzheimer's disease neurons? Nat Med. 4:1998;897-898.
99. Perry G., Zhu X., Smith M.A. Do neurons have a choice in death? Am J Pathol. 158:2001;1-2.
100. Anderson A.J., Cummings B.J., Cotman C.W. Increased immunoreactivity for Jun and Fos-related proteins in Alzheimer's disease: association with pathology. Exp Neurol. 125:1994;286-295.
101. Smith M.A., Kutty R.K., Richey P.L., et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol. 145:1994;42-47.
102. Wiese A.G., Pacifici R.E., Davies K.J. Transient adaptation of oxidative stress in mammalian cells. Arch Biochem Biophys. 318:1995;231-240.
103. Davies J.M., Lowry C.V., Davies K.J. Transient adaptation to oxidative stress in yeast. Arch Biochem Biophys. 317:1995;1-6.
104. Keyse S.M., Tyrrell R.M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA. 86:1989;99-103.
105. Rushmore T.H., King R.G., Paulson K.E., Pickett C.B. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc Natl Acad Sci USA. 87:1990;3826-3830.
106. Chao M., Zhu X., Raina A.K., et al. Sources contributing to the initiation and propagation of oxidative stress in Alzheimer's disease. Proc Indian Natl Sci Acad. B69:2003;251-260.
107. LeBel C.P., Bondy S.C. Oxidative damage and cerebral aging. Prog Neurobiol. 38:1992;601-609.
108. Mattson M.P., Chan S.L., Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev. 82:2002;637-672.
109. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
110. Schubert D., Cole G., Saitoh T., Oltersdorf T. Amyloid beta protein precursor is a mitogen. Biochem Biophys Res Commun. 162:1989;83-88.
111. Milward E.A., Papadopoulos R., Fuller S.J., et al. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 9:1992;129-137.
112. Copani A., Condorelli F., Caruso A., et al. Mitotic signaling by beta-amyloid causes neuronal death. Faseb J. 13:1999;2225-2234.
113. Hoffmann J., Twiesselmann C., Kummer M.P., Romagnoli P., Herzog V. A possible role for the Alzheimer's amyloid precursor protein in the regulation of epidermal basal cell proliferation. Eur J Cell Biol. 79:2000;905-914.
114. Schmitz A., Tikkanen R., Kirfel G., Herzog V. The biological role of the Alzheimer's amyloid precursor protein in epithelial cells. Histochem Cell Biol. 117:2002;171-180.
115. Neve R.L., McPhie D.L., Chen Y. Alzheimer's disease: a dysfunction of the amyloid precursor protein(1). Brain Res. 886:2000;54-66.
116. Chen Y., McPhie D.L., Hirschberg J., Neve R.L. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem. 275:2000;8929-8935.
117. Bruni P., Minopoli G., Brancaccio T., et al. Fe65, a ligand of the Alzheimer's beta-amyloid precursor protein, blocks cell cycle progression by down-regulating thymidylate synthase expression. J Biol Chem. 277:2002;35481-35488.
118. Marques C.A., Keil U., Bonert A., et al. Neurotoxic mechanisms caused by the alzheimer's disease-linked swedish APP mutation: oxidative stress, caspases and JNK pathway. J Biol Chem. 278:2003;28294-28302.
119. Eckert A., Steiner B., Marques C., et al. Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res. 64:2001;183-192.
120. Leutz S., Steiner B., Marques C.A., Haass C., Muller W.E., Eckert A. Reduction of trophic support enhances apoptosis in PC12 cells expressing Alzheimer's APP mutation and sensitizes cells to staurosporine-induced cell death. J Mol Neurosci. 18:2002;189-201.
121. Xu X., Yang D., Wyss-Coray T., et al. Wild-type but not Alzheimer's-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc Natl Acad Sci USA. 96:1999;7547-7552.
122. Koistinaho M., Kettunen M.I., Goldsteins G., et al. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci USA. 99:2002;1610-1615.
123. Nakagawa Y., Nakamura M., McIntosh T.K., et al. Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. J Comp Neurol. 411:1999;390-398.
124. Pedersen W.A., Culmsee C., Ziegler D., Herman J.P., Mattson M.P. Aberrant stress response associated with severe hypoglycemia in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci. 13:1999;159-165.
125. Janicki S.M., Monteiro M.J. Presenilin overexpression arrests cells in the G1 phase of the cell cycle: arrest potentiated by the Alzheimer's disease PS2(N141I)mutant. Am J Pathol. 155:1999;135-144.
126. Janicki S.M., Stabler S.M., Monteiro M.J. Familial Alzheimer's disease presenilin-1 mutants potentiate cell cycle arrest. Neurobiol Aging. 21:2000;829-836.
127. Prat M.I., Adamo A.M., Gonzalez S.A., et al. Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration. Neurosci Lett. 326:2002;9-12.
128. Soriano S., Kang D.E., Fu M., et al. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J Cell Biol. 152:2001;785-794.
129. Yuasa S., Nakajima M., Aizawa H., et al. Impaired cell cycle control of neuronal precursor cells in the neocortical primordium of presenilin-1- deficient mice. J Neurosci Res. 70:2002;501-513.
130. Nakajima M., Miura M., Aosaki T., Shirasawa T. Deficiency of presenilin-1 increases calcium-dependent vulnerability of neurons to oxidative stress in vitro. J Neurochem. 78:2001;807-814.
131. Deng G., Pike C.J., Cotman C.W. Alzheimer's-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. FEBS Lett. 397:1996;50-54.
132. Chan S.L., Culmsee C., Haughey N., Klapper W., Mattson M.P. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol Dis. 11:2002;2-19.
133. Guo Q., Furukawa K., Sopher B.L., et al. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport. 8:1996;379-383.
134. Mattson M.P., Zhu H., Yu J., Kindy M.S. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J Neurosci. 20:2000;1358-1364.
135. Guo Q., Fu W., Sopher B.L., et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 5:1999;101-106.
136. Terro F., Czech C., Esclaire F., et al. Neurons overexpressing mutant presenilin-1 are more sensitive to apoptosis induced by endoplasmic reticulum-Golgi stress. J Neurosci Res. 69:2002;530-539.
137. Grilli M., Diodato E., Lozza G., et al. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc Natl Acad Sci USA. 97:2000;12822-12827.
138. Clarke G., Collins R.A., Leavitt B.R., et al. A one-hit model of cell death in inherited neuronal degenerations. Nature. 406:2000;195-199.
139. Smith D.H., Nakamura M., McIntosh T.K., et al. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am J Pathol. 153:1998;1005-1010.